Heart Failure Pipeline Research Report 2021: Comprehensive Insights on 100+ Companies & Respective Pipeline Drugs – ResearchAndMarkets.com

Heart Failure Pipeline Research Report 2021: Comprehensive Insights on 100+ Companies & Respective Pipeline Drugs – ResearchAndMarkets.com

Heart Failure Pipeline Research Report 2021: Comprehensive Insights on 100+ Companies & Respective Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Heart Failure – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

This Heart failure – Pipeline Insight, 2021 provides comprehensive insights for approx 100+ companies and 100+ pipeline drugs in Heart failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Heart failure R&D. The therapies under development are focused on novel approaches to treat/improve Heart failure.

Heart failure Emerging Drugs Chapters

This segment of the Heart failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Heart failure Emerging Drugs

Finerenone: Bayer HealthCare Pharmaceuticals

Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block many of the harmful effects of mineralocorticoid receptor (MR) overactivation. MR overactivation is a major driver of kidney and cardiovascular damage through inflammatory and fibrotic processes. It is in phase III stage of development to treat heart failure.

IONIS-AGT-LRx: Ionis Pharmaceuticals

IONIS-AGT-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of angiotensinogen to decrease blood pressure in patients with treatment resistant hypertension (TRH). Despite availability of generic antihypertensive agents, TRH is a major contributor to cardiovascular and renal disease. It is in phase II stage of development to treat chronic heart failure.

Heart failure: Therapeutic Assessment

This segment of the report provides insights about the different Heart failure drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Heart failure

There are approx. 100+ key companies which are developing the therapies for Heart failure. The companies which have their Heart failure drug candidates in the most advanced stage, i.e. phase III include, Bayer HealthCare Pharmaceuticals.


This report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Heart failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Heart failure: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart failure therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart failure drugs.

Heart failure Report Insights

  • Heart failure Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Heart failure Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Heart failure drugs?
  • How many Heart failure drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart failure?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Heart failure therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Heart failure and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Bayer HealthCare Pharmaceuticals
  • Ionis Pharmaceuticals
  • Heartseed Inc.
  • AstraZeneca
  • Amgen
  • Sardocor Corp.
  • Intra-Cellular Therapies
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • Palatin Technologies
  • Cardiora
  • Zensun Sci. & Tech. Co., Ltd.
  • Biopeutics Co., Ltd
  • Innolife Co., Ltd.
  • SQ Innovation
  • scPharmaceuticals
  • Mesoblast, Inc
  • PhaseBio Pharmaceuticals
  • Salubris Biotherapeutics Inc
  • Actelion Pharmaceuticals
  • Torrent Pharmaceuticals Limited
  • Novo Nordisk A/S
  • Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.
  • Merck Sharp & Dohme Corp.
  • Cardior Pharmaceuticals GmbH
  • Pfizer
  • MyoKardia, Inc.
  • TransThera Biosciences Co., Ltd
  • Acceleron Pharma Inc.
  • Asklepios Biopharmaceutical, Inc.
  • Bial

Key Products

  • Finerenone
  • HS 001
  • AZD 4831
  • Omecamtiv Mecarbil
  • SRD-001
  • ITI-214
  • BMS-986259
  • LY3461767
  • PL-3994
  • CRD-102
  • rhNRG-1
  • INL1
  • SQIN-01
  • Furoscix Infusor
  • Allogeneic Mesenchymal Precursor Cells (MPC)
  • PB1046
  • JK07
  • Macitentan
  • TRC041266
  • Semaglutide
  • TSG-01
  • Ertugliflozin
  • CDR132L
  • Sildenafil Citrate
  • Mavacamten
  • TT-00920
  • Sotatercept
  • NAN-101
  • BIA 5-1058

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/php1x2



Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900